NeueHealth (NYSE:NEUE) Director Sells $28,316.25 in Stock

Key Points

• Director Scott Sandell sold 4,195 shares of NeueHealth stock for a total of $28,316.25, reducing his position by 0.85% to 488,702 shares.
• NeueHealth reported a quarterly loss of ($1.68) EPS, beating analyst expectations but falling short on revenue estimates with $209.08 million against a forecast of $249.50 million.
• The stock has an average price target of $7.00, with a current market capitalization of $60.94 million and an average rating of "Reduce" from analysts.

NeueHealth, Inc. (NYSE:NEUE - Get Free Report) Director Scott Sandell sold 4,195 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $6.75, for a total transaction of $28,316.25. Following the completion of the transaction, the director owned 488,702 shares in the company, valued at $3,298,738.50. The trade was a 0.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

NeueHealth Stock Performance

NEUE remained flat at $6.75 during trading hours on Monday. The firm's 50 day moving average is $6.72 and its 200-day moving average is $6.72. NeueHealth, Inc. has a 1-year low of $3.79 and a 1-year high of $7.66. The stock has a market capitalization of $60.94 million, a price-to-earnings ratio of -0.42 and a beta of 0.59.

NeueHealth (NYSE:NEUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.68) EPS for the quarter, beating the consensus estimate of ($4.77) by $3.09. The firm had revenue of $209.08 million during the quarter, compared to analyst estimates of $249.50 million. Equities research analysts forecast that NeueHealth, Inc. will post -9.13 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of NeueHealth in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, NeueHealth currently has an average rating of "Reduce" and an average price target of $7.00.

Institutional Investors Weigh In On NeueHealth

An institutional investor recently bought a new position in NeueHealth stock. Skandinaviska Enskilda Banken AB publ purchased a new stake in NeueHealth, Inc. (NYSE:NEUE - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 29,182 shares of the company's stock, valued at approximately $201,000. Skandinaviska Enskilda Banken AB publ owned approximately 0.32% of NeueHealth as of its most recent SEC filing. Institutional investors own 63.88% of the company's stock.

NeueHealth Company Profile

NeueHealth, Inc, a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.